The GV-backed stem cell drug developer has set terms for an initial public offering that would raise between $300m and $345m.

Lepas by Bayer led a round for anti-allergy drug and food treatment developer Ukko that also featured Continental Grain.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

The autoimmune disease drug developer's series A round has closed at $42.4m after Roche Venture Fund added funding to a first close co-led by AbbVie Ventures.

The mental health benefits platform, which counts Providence Health and Services as an investor, doubled its valuation to $2.3m in the series E round.

Main Street Advisors has invested $9m in the plant-based formula provider through a round already backed by Kaiser Permanente Ventures.

SR One reinvested in a series B round for the degenerative disorder drug developer that was led by venture fund Logos Capital.

The cancer drug developer's $12.8m seed round included Eli Lilly, and Lilly New Ventures' Brad Robling is a board observer.

The corporate-backed Cardeation Capital took part in a round for the medical device developer that was led by an unnamed medical technology provider.

Clerkie, Ketos, MedHaul, Perch, Shift, Superpedestrian and Vyv have all received funding from the banking group’s $200m Impact Fund.